Apricus Biosciences And Vitaros: Update On The Launch
MTF Investing - at Seeking Alpha - Wed Dec 24, 12:21PM CST
APRI: 1.01 (+0.03)
Apricus Biosciences Announces Year-End 2014 Update and 2015 Plans to Advance Its Clinical Pipeline and Further Commercialize Its Erectile Dysfunction Drug Vitaros(R)
GlobeNewswire - Mon Dec 22, 6:30AM CST
Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today reviewed its 2014 corporate progress and its clinical development and commercialization plans for 2015.
APRI: 1.01 (+0.03)
New medical chief at Apricus
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 9:52AM CST
APRI: 1.01 (+0.03)
Apricus Biosciences Appoints Barbara Troupin, M.D. as Chief Medical Officer
GlobeNewswire - Mon Dec 15, 6:39AM CST
Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced the appointment of Barbara Troupin, M.D., as the Company's Chief Medical Officer. Dr. Troupin brings to Apricus over 15 years of experience in the areas of pharmaceutical clinical development and medical affairs. She will report to Richard Pascoe, Apricus' Chief Executive Officer, and her appointment is effective immediately.
APRI: 1.01 (+0.03)
Apricus Biosciences Announces First Patient Enrolled in Phase 2a Clinical Trial for RayVa(TM) in Patients With Raynaud's Phenomenon
GlobeNewswire - Thu Dec 04, 7:06AM CST
Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the first patient has been enrolled in the Phase 2a clinical trial to evaluate RayVa, Apricus' product candidate for the treatment of Raynaud's phenomenon secondary to scleroderma. RayVa combines alprostadil, a potent vasodilator, with Apricus' proprietary permeation enhancer DDAIP.HCl, and is applied as an on-demand topical cream to affected extremities.
APRI: 1.01 (+0.03)
Apricus Biosciences names Brian T. Dorsey as its chief development officer
M2 - Wed Dec 03, 7:08AM CST
Biopharmaceutical company Apricus Biosciences (NasdaqCM:APRI) revealed on Tuesday the election of Brian T. Dorsey as its chief development officer.
APRI: 1.01 (+0.03)
Apricus Biosciences Appoints Brian T. Dorsey as Chief Development Officer
GlobeNewswire - Tue Dec 02, 6:30AM CST
Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced the appointment of Brian T. Dorsey as the Company's Chief Development Officer, a newly established position. Mr. Dorsey brings to Apricus over 20 years of experience in the pharmaceutical industry across early- and late-stage development programs, as well as with marketed products. He will report to Richard Pascoe, Apricus' Chief Executive Officer. His appointment is effective immediately.
APRI: 1.01 (+0.03)
Apricus Biosciences' (APRI) CEO Rich Pascoe on Q3 2014 Results -- Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 11:29AM CST
APRI: 1.01 (+0.03)
Apricus Biosciences beats by $0.02, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 6:55AM CST
APRI: 1.01 (+0.03)
Apricus Biosciences Announces Third Quarter 2014 Financial Results and Provides Corporate Update
GlobeNewswire - Mon Nov 10, 6:07AM CST
Company Recently Expanded Development Pipeline with U.S. In-License of Fispemifene
APRI: 1.01 (+0.03)
Apricus Biosciences to Host Third Quarter 2014 Earnings Conference Call and Webcast Live on Monday, November 10, 2014
ACCESSWIRE - Fri Nov 07, 3:06PM CST
SAN DIEGO, CA / ACCESSWIRE / November 7, 2014 / Apricus Biosciences, Inc. (NASDAQ:APRI) will host a conference call and live webcast to discuss the results of the third quarter 2014, to be held Monday, November 10, 2014 at 8:30 AM Eastern Time.
APRI: 1.01 (+0.03)
Apricus Biosciences to Present at Three Upcoming Investor Conferences in November and December of 2014
GlobeNewswire - Wed Nov 05, 6:46AM CST
Apricus Biosciences, Inc. (Nasdaq:APRI), a developer of biopharmaceutical therapeutics for urology and rheumatology disorders, today announced that members of senior management will present at the following three investor conferences, each of which will be webcast live and for replay at http://www.apricusbio.com/investor-relations/presentations/.
APRI: 1.01 (+0.03)
Apricus Biosciences Announces Corporate Update and Third Quarter 2014 Financial Results Conference Call
GlobeNewswire - Tue Nov 04, 6:30AM CST
Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines to meet the needs of patients, today announced that the Company's third quarter financial results will be released on Monday, November 10, 2014. Company management will host a conference call on Monday, November 10, 2014, at 8:30 a.m. Eastern Time to discuss the financial results and other recent corporate highlights.
APRI: 1.01 (+0.03)
Apricus Biosciences Announces the Launch of Its Novel Topical Treatment for Erectile Dysfunction in Belgium by Sandoz
GlobeNewswire - Mon Nov 03, 5:00AM CST
Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines to meet the needs of patients, today announced the launch of Vytaros in Belgium by the Sandoz Division of the Novartis Group of Companies ("Sandoz"
APRI: 1.01 (+0.03)
Apricus Expands Development Pipeline With the In-Licensing of U.S. Rights for Fispemifene, a Phase 2b Ready Asset, From Forendo Pharma Targeting Urological Conditions in Men
GlobeNewswire - Mon Oct 20, 1:00AM CDT
-- Apricus Funds Upfront License Fee and 2015 Phase 2b Development Cost with $10 Million Venture Debt Financing --
APRI: 1.01 (+0.03)
Apricus Biosciences wins notice of allowance in the US for patent application for RayVa
M2 - Tue Oct 14, 7:23AM CDT
Biopharmaceutical company Apricus Biosciences (NasdaqCM:APRI) revealed on Monday the receipt of the US Patent and Trademark Office's (USPTO) Notice of Allowance for RayVa for treating Raynaud's phenomenon in the US.
APRI: 1.01 (+0.03)
Apricus Biosciences Announces Notice of Allowance of U.S. Patent Application for RayVa(TM)
GlobeNewswire - Mon Oct 13, 6:09AM CDT
Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines to meet the needs of patients, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application Serial Number 14/110,348 (the '348 application). The patent application generally is directed to methods and compositions for treating Raynaud's phenomenon, including claims related to treating Raynaud's phenomenon that is secondary to systemic sclerosis.
APRI: 1.01 (+0.03)
Apricus Biosciences to Present at the 13th Annual BIO Investor Forum
GlobeNewswire - Wed Oct 01, 9:21AM CDT
Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines to meet the needs of patients, today announced that Richard Pascoe, Chief Executive Officer, will present at the 13 Annual BIO Investor Forum on Wednesday, October 8, 2014 at 11:30 a.m. Pacific Time. The meeting will be held at the Palace Hotel in San Francisco, CA. Mr. Pascoe will provide an update on the successful European launch of Vitaros, the Company's topical treatment for erectile dysfunction. Mr. Pascoe will also provide an overview of the Apricus drug candidate, RayVa, targeted to treat the circulatory condition Raynaud's phenomenon.
APRI: 1.01 (+0.03)
Apricus CEO to Discuss Company's Drug Portfolio, Including Its Topical Cream for Erectile Dysfunction, Vitaros(R), LIVE on iHeart (Clear Channel) Business Talk Radio DFW 1190AM on Sept. 25, 2014
Marketwire - Wed Sep 24, 1:36PM CDT
Richard Pascoe, CEO of biopharmaceutical developer, Apricus Biosciences, Inc. (NASDAQ: APRI) will be interviewed live tomorrow on iHeart (Clear Channel) Business Talk Radio. Mr. Pascoe will discuss the Company's prescription erectile dysfunction treatment Vitaros(R), which was launched commercially in the UK, Germany and Sweden this year and is expected to roll out in other European countries later this year and in 2015. He will also review Apricus' development portfolio, which includes drug candidate RayVa(TM) targeted to treat the circulatory condition, Raynaud's phenomenon secondary to scleroderma. Raynaud's affects the extremities in an estimated 3 - 5% of the U.S. population. Femprox(R), Apricus' third drug candidate, is targeted for the treatment of female sexual interest / arousal disorder.
APRI: 1.01 (+0.03)
Female Hypoactive Sexual Desire Disorder Therapeutics Pipeline Review, H2 2014 - 3 Companies & 7 Drug Profiles
M2 - Wed Sep 24, 5:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cpm6jv/female_hypoactive) has announced the addition of the "Female Hypoactive Sexual Desire Disorder - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Female Hypoactive Sexual Desire Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Female Hypoactive Sexual Desire Disorder and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Female Hypoactive Sexual Desire Disorder - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Female Hypoactive Sexual Desire Disorder and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Female Hypoactive Sexual Desire Disorder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Female Hypoactive Sexual Desire Disorder pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Apricus Biosciences, Inc. - Palatin Technologies, Inc. - ANI Pharmaceuticals, Inc. Drug Profiles - flibanserin - testosterone - alprostadil - bremelanotide - (sildenafil testosterone) - (bupropion hydrochloride trazodone hydrochloride) - (buspirone hydrochloride testosterone) For more information visit http://www.researchandmarkets.com/research/cp...hypoactive
ANIP: 55.24 (+1.79), PTN: 0.71 (+0.04), APRI: 1.01 (+0.03)